Years Lived With Disability in Longevity Research

Longevity research can appear successful when survival increases, even if the additional years include substantial pain, sensory loss, cognitive impairment, or restricted function. Years lived with disability provide a standardized way to represent this non-fatal health loss across diseases, injuries, ages, sexes, places, and time periods. The measure therefore adds information that death counts and life expectancy cannot supply on their own. [1] [2] [5]

Who This Is Useful For

This page is useful for readers evaluating whether longer lives are also healthier lives. It explains what YLD estimates represent, how they enter broader longevity measures, why population ageing changes their interpretation, and which methodological choices limit comparisons across studies. [1] [5] [7]

What a YLD Measures

In prevalence-based Global Burden of Disease analyses, a health state produces YLDs when people live with it during a specified period. Its prevalence is multiplied by a disability weight: a number on a scale anchored at zero for full health and one for a health loss equivalent to death. The unit is best understood as an equivalent amount of full-health time lost, aggregated across a population. [1] [2] [3]

For example, 1,000 people living for one year in a health state assigned a disability weight of 0.2 would contribute 200 YLDs for that period. This calculation does not assert that 200 particular people were disabled for a full year; it expresses the modeled loss across all 1,000 people on a common scale. [1] [3]

How the Estimate Is Built

Relationship to DALYs and Healthy Life Expectancy

YLDs describe non-fatal health loss. Years of life lost (YLLs) describe premature mortality relative to a reference life table, and DALYs are the sum of YLDs and YLLs. A disease that rarely causes death can therefore have a high YLD burden, while a rapidly fatal disease may be represented mainly through YLLs. [1] [5]

HALE asks a different question: how many years a hypothetical population member can expect to live in full health under the mortality and morbidity conditions of a given period. GBD estimates use age-specific mortality together with YLDs per person to adjust total life expectancy for time lived in less than full health. HALE is therefore an expectancy measure, whereas YLD is a burden measure. [1] [5]

Disability-free life expectancy is related but not necessarily identical to HALE. It commonly divides life into disabled and non-disabled states using a defined survey threshold, while HALE can weight multiple degrees of health loss. Both depend on the health definition and period data used, so neither is a direct forecast of one individual's future. [7] [11]

Why YLDs Matter in Longevity Research

Mortality-only endpoints can miss changes that preserve survival without preserving function. YLDs make non-fatal outcomes commensurable, allowing analyses to compare how much estimated health loss is linked to musculoskeletal, sensory, neurological, mental, metabolic, and other conditions. They also reveal why a condition can be important to healthspan even when it is not a leading cause of death. [1] [2]

Low back pain illustrates the distinction: GBD 2021 analyses identified it as the leading global cause of YLDs in 2020, despite its burden being primarily non-fatal. This does not make one condition a complete proxy for healthspan; it shows why survival statistics alone understate some major sources of lived health loss. [8]

Counts, Rates, and Age Standardisation

A YLD count describes the total modeled burden in a population. A crude rate divides that count by the population, while an age-standardised rate reweights age-specific rates to a standard population so that places or years with different age structures can be compared more fairly. GBD reports both counts and age-standardised rates because they answer different questions. [1] [5]

Total YLDs can rise because a population grows, becomes older, experiences more disease at the same age, or some combination of these changes. An age-standardised rate can remain stable or decline while the count increases. Conversely, standardisation is useful for comparison but does not describe the actual service burden faced by a population with its real age structure. [1] [8]

Longer Survival and the Compression of Morbidity

A central longevity question is whether gains in life expectancy are accompanied by proportionally larger gains in healthy life expectancy. YLD counts alone cannot answer this because they do not combine morbidity with the mortality schedule or show when disability begins within an individual's life course. HALE, disability-free life expectancy, and longitudinal transition analyses are more direct tools for examining whether morbidity is compressed into a smaller part of life or expands across more years. [5] [7] [11]

Historical results need not be uniform across age or sex. One United States analysis covering 1970 to 2010 found increases in both disabled and disability-free life expectancy, with the balance differing at birth and at age 65. This illustrates why a single population-wide claim of compression or expansion can conceal important subgroup and starting-age differences. [7]

Limitations and Sources of Uncertainty

YLD estimates are partly modeled because comparable direct measurements do not exist for every disease, age, location, sex, and year. GBD combines many sources, adjusts non-standard case definitions, estimates missing quantities, and propagates uncertainty through the analysis. Reported uncertainty intervals are therefore essential rather than optional decoration around a point estimate. [1]

Disability weights are judgments about the relative loss of health described by standardized vignettes; they are not direct measurements from a biological instrument. Large valuation studies have found broad commonality across populations, but revisions to descriptions and methods can materially change some weights. Reviews also document variation among disability-weight studies, especially for mild states. [3] [4] [9]

Multimorbidity is particularly important in later life. Adding condition-specific weights directly can double-count overlapping loss, but assuming independence among diseases or combining weights multiplicatively can also misrepresent real patterns of co-occurrence. Comparative work shows that the chosen correction method can alter burden estimates. [2] [6]

A diagnostic label also does not imply one fixed level of disability. Severity distributions attempt to represent variation from asymptomatic to severe states, but available surveys and mappings may not capture every geography or dimension of lived function equally well. [10]

Evidence Quality and Interpretation

Confidence is strong in the conceptual distinction between fatal and non-fatal health loss and in the value of reporting them separately. The YLD framework is transparent enough to show how prevalence, severity weights, and comorbidity assumptions enter the estimate, and large GBD analyses report uncertainty intervals across locations and causes. [1] [2]

Confidence is lower when small differences are compared across data-poor settings, survey instruments, or methodological revisions. YLDs are most informative when the version of the estimation framework, age range, cause definition, metric type, and uncertainty interval are all specified. [1] [4] [9]

What This Does Not Mean

• It does not mean one YLD corresponds to one identifiable person spending one calendar year with a legally or clinically defined disability. [1] [3]
• It does not mean disability weights measure a person's social worth, productivity, or entitlement to care; they quantify modeled health loss for population comparisons. [3] [4]
• It does not mean a larger YLD count proves that age-specific health has deteriorated, because population size and age structure also affect counts. [1] [8]
• It does not mean a lower YLD burden necessarily reflects longer survival; mortality must be examined separately or through DALYs and health-expectancy measures. [1] [5]
• It does not mean all people with the same diagnosis experience the same severity or functional consequences. [10]

Practical Interpretation Examples

• If total YLDs rise but the age-standardised rate falls: Population growth or ageing may be increasing the total burden even as health loss at comparable ages declines. [1] [8]
• If life expectancy rises while HALE rises more slowly: Some of the added survival is expected to be spent with health loss under the period's estimated conditions. [5]
• If a low-mortality condition ranks highly by YLDs: High prevalence, long duration, or appreciable severity can create substantial population burden without many direct deaths. [2] [8]
• If two studies report different YLD estimates: Check the population, year, age range, case definition, disability-weight set, severity distribution, comorbidity method, and whether the result is a count or rate. [1] [6] [9] [10]

Summary

Years lived with disability extend longevity analysis beyond survival by estimating the population's non-fatal health loss. Their main strength is comparability across many health states; their main constraint is that the result inherits assumptions and uncertainty from prevalence data, severity valuation, and comorbidity modeling. Read alongside life expectancy, HALE, YLLs, and age-specific functional measures, YLDs help distinguish more years alive from more years lived in full health. [1] [5] [6] [9]

References

1. GBD 2021 Diseases and Injuries Collaborators. (2024). Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. https://pmc.ncbi.nlm.nih.gov/articles/PMC11122111/
2. Vos, T., Flaxman, A. D., Naghavi, M., et al. (2012). Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. https://pmc.ncbi.nlm.nih.gov/articles/PMC6350784/
3. Salomon, J. A., Vos, T., Hogan, D. R., et al. (2012). Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. The Lancet. https://pubmed.ncbi.nlm.nih.gov/23245605/
4. Salomon, J. A., Haagsma, J. A., Davis, A., et al. (2015). Disability weights for the Global Burden of Disease 2013 study. The Lancet Global Health. https://pubmed.ncbi.nlm.nih.gov/26475018/
5. GBD 2017 DALYs and HALE Collaborators. (2018). Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. https://pmc.ncbi.nlm.nih.gov/articles/PMC6252083/
6. Hilderink, H. B. M., Plasmans, M. H. D., Snijders, B. E. P., et al. (2016). Accounting for multimorbidity can affect the estimation of the burden of disease: a comparison of approaches. Archives of Public Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC4993005/
7. Crimmins, E. M., Zhang, Y., & Saito, Y. (2016). Trends over 4 decades in disability-free life expectancy in the United States. American Journal of Public Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC4984740/
8. GBD 2021 Low Back Pain Collaborators. (2023). Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. The Lancet Rheumatology. https://pubmed.ncbi.nlm.nih.gov/37273833/
9. Haagsma, J. A., Polinder, S., Cassini, A., Colzani, E., & Havelaar, A. H. (2014). Review of disability weight studies: comparison of methodological choices and values. Population Health Metrics. https://pmc.ncbi.nlm.nih.gov/articles/PMC4445691/
10. Burstein, R., Fleming, T., Haagsma, J. A., et al. (2015). Estimating distributions of health state severity for the Global Burden of Disease study. Population Health Metrics. https://pmc.ncbi.nlm.nih.gov/articles/PMC4650517/
11. Imai, K., & Soneji, S. (2007). On the estimation of disability-free life expectancy: Sullivan's method and its extension. Journal of the American Statistical Association. https://pmc.ncbi.nlm.nih.gov/articles/PMC4533834/